Di Wu

Di Wu

Auto-generated profile, based on publicly available information

Di Wu

Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDi Wu
Di Wu
YLYong Li
Yong Li
PXPengfei Xu
Pengfei Xu
QFQi Fang
Qi Fang
FCFei Cao
Fei Cao
XLXuekui Liu
Xuekui Liu
Neoadjuvant chemoimmunotherapy has emerged as a potential treatment option for resectable head and neck squamous cell carcinoma (HNSCC). In this single-arm phase II trial (NCT04826679), patients with resectable locally advanced HNSCC (T2‒T4, N0‒N3b, M0) received neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (60 mg/m2) intravenously on day one of each three-week cycle for three cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints included pathologic complete response (pCR), major pathologic response (MPR), two-year progression-free survival rate, two-year overall survival rate, and toxicities. Here, we report the perioperative outcomes; survival outcomes were not mature at the time of data analysis. Between April 19, 2021 and March 17, 2022, 48 patients were enrolled and received neoadjuvant therapy, 27 of whom proceeded to surgical resection and remaining 21 received non-surgical therapy. The ORR was 89.6% (95% CI: 80.9, 98.2) among 48 patients who completed neoadjuvant therapy. Of the 27 patients who underwent surgery, 17 (63.0%, 95% CI: 44.7, 81.2) achieved a MPR or pCR, with a pCR rate of 55.6% (95% CI: 36.8, 74.3). Treatment-related adverse events of grade 3 or 4 occurred in two patients. This study meets the primary endpoint showing potential efficacy of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin, with an acceptable safety profile, in patients with resectable locally advanced HNSCC.


15 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FCFei Cao
Fei Cao
YLYan Li
Yan Li
QFQi Fang
Qi Fang
RLRuobin Lin
Ruobin Lin
ZZZheng Zhao
Zheng Zhao
XLXuekui Liu
Xuekui Liu
Purpose: Preclinical and clinical findings suggest that PD-1/cytotoxic T lymphocyte–associated protein 4 bispecific antibodies may offer synergistic antitumor activity. This study aimed to explore the efficacy and safety of cadonilimab combined with neoadjuvant chemotherapy in locally advanced, resectable head and neck squamous cell carcinoma. Patients and Methods: Eligible patients were consecutively enrolled and received cadonilimab (10 mg/kg) and chemotherapy (docetaxel, 75 mg/m2 plus cisplatin, 60 mg/m2) every 3 weeks for three cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate, pathologic complete response, major pathologic response (MPR), safety, progression-free survival, and overall survival. Analyses of biomarkers and tumor-infiltrating immune cell subsets were conducted. This study is registered with ClinicalTrials.gov (NCT06023875). Results: Thirty patients were included from July 2023 to December 2023. The median age was 55 years (range: 26–69), and 27 (90.0%) patients were male. The ORR was 83.3%, disease control rate was 100.0%, MPR rate was 76.7%, and pathologic complete response rate was 50.0%. All patients experienced treatment-related adverse events. Grade 3 treatment-related adverse events were reported in 7 (23.3%) patients. Progression-free survival and overall survival data were not yet mature as of the cutoff date (February 1, 2025). Subgroup analysis revealed no significant differences in biomarker expression. A higher baseline infiltration of M1-like macrophages in the tumor stroma was associated with better treatment efficacy. Conclusions: Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.

1 January 2025 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
ZZZheng Zhao
Zheng Zhao
YHYingbin Huang
Yingbin Huang
JMJunhao Mai
Junhao Mai
FCFei Cao
Fei Cao
QFQi Fang
Qi Fang
XLXuekui Liu
Xuekui Liu
Zhao Z, et al. J Breast Cancer. 2025 Oct;28:e37. https://doi.org/10.4048/jbc.2025.0079


15 September 2025
Verified
Other
Open access
FCFei Cao
Fei Cao
YLYan Li
Yan Li
QFQi Fang
Qi Fang
RLRuobin Lin
Ruobin Lin
ZZZheng Zhao
Zheng Zhao
XLXuekui Liu
Xuekui Liu
Purpose:Preclinical and clinical findings suggest that PD-1/cytotoxic T lymphocyte–associated protein 4 bispecific antibodies may offer synergistic antitumor activity. This study aimed to explore the efficacy and safety of cadonilimab combined with neoadjuvant chemotherapy in locally advanced, resectable head and neck squamous cell carcinoma.Patients and Methods:Eligible patients were consecutively enrolled and received cadonilimab (10 mg/kg) and chemotherapy (docetaxel, 75 mg/m2 plus cisplatin, 60 mg/m2) every 3 weeks for three cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate, pathologic complete response, major pathologic response (MPR), safety, progression-free survival, and overall survival. Analyses of biomarkers and tumor-infiltrating immune cell subsets were conducted. This study is registered with ClinicalTrials.gov (NCT06023875).Results:Thirty patients were included from July 2023 to December 2023. The median age was 55 years (range: 26–69), and 27 (90.0%) patients were male. The ORR was 83.3%, disease control rate was 100.0%, MPR rate was 76.7%, and pathologic complete response rate was 50.0%. All patients experienced treatment-related adverse events. Grade 3 treatment-related adverse events were reported in 7 (23.3%) patients. Progression-free survival and overall survival data were not yet mature as of the cutoff date (February 1, 2025). Subgroup analysis revealed no significant differences in biomarker expression. A higher baseline infiltration of M1-like macrophages in the tumor stroma was associated with better treatment efficacy.Conclusions:Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.